JAB 21822
As of the edition of 20 October 2026, JAB 21822 is a drug known only by a code name: in active development; acts on KRAS.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| KRAS | GTPase KRas | P01116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jacobio Pharmaceuticals | Lead sponsor of trials | 2021 to now |
| Allist Pharmaceuticals | Lead sponsor of trials | 2022 to now |